

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for inducing an antigen specific systemic and ~~rectal~~ colorectal mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a ~~rectal~~ colorectal mucosal tissue of the subject with a composition comprising a chimeric peptide having the amino acid sequence KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9), wherein the colorectal mucosal tissue is the only site of contact.
2. (Canceled)
3. (Original) The method of claim 1, wherein said composition further comprises an adjuvant.
4. (Previously Presented) The method of claim 3, wherein the adjuvant is cholera toxin (CT), mutant cholera toxin (MCT), or mutant-*E. coli* heat labile enterotoxin (MLT).
5. (Original) The method of claim 1, further comprising administering a purified cytokine to the subject.
6. (Currently amended) The method of claim 5, wherein the cytokine is contacted with a colorectal mucosal surface of the subject.

7. (Previously Presented) The method of claim 5, wherein the purified cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

8. (Original) The method of claim 1, further comprising administering purified interferon- γ to the subject.

9. (Original) The method of claim 8, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

10. (Original) The method of claim 5, further comprising administering purified interferon- γ to the subject.

11. (Original) The method of claim 10, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

12. (Previously Presented) The method of claim 1, wherein said composition further comprises a purified cytokine, wherein the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

13. (Original) The method of claim 1, wherein said composition further comprises purified interferon- γ .

14. (Original) The method of claim 12, wherein said composition further comprises purified interferon- γ .

15-24. (Canceled)

25. (Currently amended) A method for inducing an antigen specific systemic and rectal colorectal mucosal CTL response in a mammalian subject, comprising contacting a rectal colorectal mucosal tissue of the subject with a composition comprising a chimeric peptide having the amino acid sequence KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9), wherein said composition does not comprise an adjuvant, and wherein the colorectal mucosal tissue is the only site of contact.

26. (Original) The method of claim 25, further comprising administering a purified cytokine to the subject.

27. (Currently amended) The method of claim 26, wherein the cytokine is contacted with a colorectal mucosal surface of the subject.

28. (Previously Presented) The method of claim 27, wherein the purified cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

29. (Original) The method of claim 25, further comprising administering purified interferon- γ to the subject.

30. (Original) The method of claim 29, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

31. (Original) The method of claim 26, further comprising administering purified interferon- γ to the subject.

32. (Original) The method of claim 31, wherein the purified interferon- γ is contacted with a mucosal surface of the subject.

33. (Previously Presented) The method of claim 25, wherein said composition further comprises a purified cytokine; wherein the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

34. (Original) The method of claim 25, wherein said composition further comprises purified interferon- γ .

35. (Original) The method of claim 33, wherein said composition further comprises purified interferon- γ .

36-69. (Canceled)

70. (New) The method of claims 1 or 25, further comprising administering a purified interleukin-12 (IL-12) protein to the subject.

71. (New) The method of claim 70, wherein the IL-12 protein is contacted with a colorectal mucosal surface of the subject.